Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506761 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2TSHRCASP1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL29192938 | 0.98 | SMN1; SMN2 (0.63) | SMN1; SMN2TSHRCASP1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL4374969 | 0.98 | SMN1; SMN2 (0.63) | SMN1; SMN2TSHRCASP1MAPTKDM4E | |
| Cyclopropane SCHEMBL29077525 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2TSHRCASP1MAPTKDM4E | |
| Cyclopropane Carboxylic Acid SCHEMBL28423298 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2TSHRCASP1MAPTKDM4E | |
| SCHEMBL3790275 | 0.84 | ALDH1A1 (0.60) | SMN1; SMN2TSHRCASP1MAPTKDM4E | |
| SCHEMBL10791990 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2TSHRCASP1MAPTKDM4E | |
| SCHEMBL30219241 | 0.82 | ALDH1A1 (0.65) | SMN1; SMN2TSHRCASP1MAPTKDM4E | |
| SCHEMBL1086528 | 0.82 | ALDH1A1 (0.65) | SMN1; SMN2TSHRCASP1MAPTKDM4E | |
| SCHEMBL10617951 | 0.82 | ALDH1A1 (0.54) | SMN1; SMN2TSHRCASP1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 489 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180188-B2 | Antifibrotic compounds and related methods | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-12-31 | — | — | US | claimed |
| CN-114797676-B | Production device and processing method of 2, 4-difluorobenzonitrile | 江西国化实业有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-117110458-A | Method for detecting halogenated benzamide by solid phase extraction-liquid chromatography tandem mass spectrometry | 浙江工业大学 | 2023-11-24 | — | — | CN | claimed |
| EP-4153177-A1 | ANTIFIBROTIC COMPOUNDS AND RELATED METHODS | Florida State University Research Foundation, Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| US-20230090542-A1 | Antifibrotic Compounds And Related Methods | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2023-03-23 | — | — | US | claimed |
| US-11548874-B2 | Antifibrotic compounds and related methods | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-01-10 | — | — | US | claimed |
| CN-114797676-A | Production device and processing method of 2, 4-difluorobenzonitrile | 江西国化实业有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-20210363131-A1 | Antifibrotic Compounds And Related Methods | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2021-11-25 | — | — | US | claimed |
| WO-2021236410-A1 | ANTIFIBROTIC COMPOUNDS AND RELATED METHODS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-11-25 | — | — | WO | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| JP-2002501024-A | — | — | 2002-01-15 | — | — | JP | claimed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | claimed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2001057024-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2001-08-09 | — | — | WO | claimed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | claimed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | claimed |
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | claimed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | claimed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548874-B2 | Antifibrotic compounds and related methods | COL1A1, COL2A1, COLGALT1 | SMN1; SMN2 2928/4885TSHR 4667/4885CASP1 682/4885 |
| US-12180188-B2 | Antifibrotic compounds and related methods | COL1A1, COL2A1, COLGALT1 | SMN1; SMN2 2928/4885TSHR 4667/4885CASP1 682/4885 |
| US-20230090542-A1 | Antifibrotic Compounds And Related Methods | COL1A1, COL2A1, COLGALT1 | SMN1; SMN2 2928/4885TSHR 4667/4885CASP1 682/4885 |
| US-20210363131-A1 | Antifibrotic Compounds And Related Methods | COL1A1, COL2A1, COLGALT1 | SMN1; SMN2 2928/4885TSHR 4667/4885CASP1 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.